Blood (ASH Annual Meeting Abstracts) 2006 108: Abstract 2763© 2006 American Society of HematologyThis Article Services Email this article to a friend Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sacchi, S. Articles by Baldini, L. Search for Related Content PubMed Articles by Sacchi, S. Articles by Baldini, L. Social Bookmarking What's this? Poster Board #-Session: 941-II Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. Stefano Sacchi, MD1, Samantha Pozzi, MD1,*, Raffaella Marcheselli, BS1,*, Stefano Luminari, MD1,*, Massimo Federico, MD1, Alessandra Tucci, MD2,*, Francesco Merli, MD3,*, Loretta Orsucci, MD4,*, Giulia Cervetti, MD5,*, Ubaldo Occhini, MD6,*, Marina Liberati, MD7,*, Vincenzo Callea, MD8,*, Maura Brugiatelli, MD9 and Luca Baldini, MD10,* 1 Dipartimento di Oncologia ed Ematologia, Universita di Modena, Modena, Italy; 2 Dipartimento di Medicina Interna, Ospedale, Brescia, Italy; 3 Dipartimento di Ematologia, Ospedale, Reggio Emilia, Italy; 4 Dipartimento di Ematologia, Ospedale, Torino, Italy; 5 Dipartimento di Ematologia, Universita di Pisa, Pisa, Italy; 6 Servizio di Ematologia, Ospedale, Arezzo, Italy; 7 Ist. Scienze Oncologiche, Universita di Perugia, Perugia, Italy; 8 Dipartimento di Ematologia, Ospedale, Reggio Calabria, Italy; 9 Divisione di Ematologia, Ospedale, Messina, Italy and 10 Dipartimento di Scienze Mediche, Universita di Milano, Milano, Italy . AbstractFifty-four Pts entered this trial between January 2000 and December 2002. Eligible Pts had histologic documentation of CD 20+ relapsed FL, according to the revised European/American Lymphoma classification, that required treatment, measurable lesion, and an ECOG performance status of 0 or 1. Pts were further required to be aged 18–70 years, and to have undergone < 3 previous lines of chemotherapy. Pts received FC + R chemoimmunotherapy consisting of F 25 mg/m2 and C 300 mg/m2/day for 3 consecutive days every 3 weeks for 4 cycles. R 375 mg/m2 I.V. infusion was administered starting 2 weeks following the first FC course and then on day 1 of each cycle thereafter. Clinical response were defined according to the International Working Group recommendations. BCL 2 analysis was performed by PCR assay. DR, TTP and OS were analyzed by Kaplan-Meier method. Cox analysis was used to analyse the association of baseline prognostic factors with response to treatment, DR,TTP and OS. The overall response rate for all 54 Pts by ITT analysis was 90%; forty Pts (74%), obtained complete responses. Progression occurred in 3 Pts ( 6% ) and 2 Pts dropped out of the trial: 1 for toxicity and 1 refused to start with therapy. A univariate analysis of baseline prognostic factors demonstrated that none of these factors predicted for response to treatment. There were 29 Pts out of 45 tested, positive for BCL 2 before therapy. Among these, 22 Pts were evaluated after treatment and 19 ( 86%) converted to BCL negativity. At last follow up (FU), 40 Pts were alive, 31 with ongoing response and 9 with progressive disease. The median DR, TTP and OS have not been reached after a median FU time of 45 months ( range, 1 to 74 months ). The median DR in the 49 Pts who have reached CR or PR was 35 months ( range, 6 to 70 months). None of the baseline prognostic characteristics was significantly related to DR. The median TTP in all 54 Pts, was 36 months ( range, 1 to 74 months ).BCL2 positivity and < 2 previous treatments were related with better TTP (p<0.05 ) OS rate at 4 years was 75%. Toxicity was evaluable in 52 Pts. The most common severe side effects were hematologic, and included 21 cases of neutropenia, 3 cases of thrombocytopenia and 2 cases of anemia. Infectious complications manifested in 3 Pts and 1 died for pneumonitis. Treatment delays of 1–3 weeks was necessary in 12 patients. The results of our trial have demonstrated that FC+R chemoimmunotherapy is active and relatively well tolerated. The OR rate of 90%, associated with an excellent molecular remission rate, and the mean DR of 35 months compares favourably with the results obtained in other trials in similar subset of patients and supports the use of an FC+R arm in future controlled trials.

Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL / Sacchi, Stefano; Pozzi, Samantha; Marcheselli, Raffaella; Luminari, Stefano; Federico, Massimo; Alessandra, Tucci; Francesco, Merli; Loretta, Orsucci; Giulia, Cervetti; Ubaldo, Occhini; Marina, Liberati; Vincenzo, Callea; Maura, Brugiatelli; Luca, Baldini. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 108:(2006), pp. 2763-2763. ((Intervento presentato al convegno 48th ASH 2006 tenutosi a nd nel dic 2006.

Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL.

SACCHI, Stefano;POZZI, Samantha;MARCHESELLI, Raffaella;LUMINARI, Stefano;FEDERICO, Massimo;
2006

Abstract

Blood (ASH Annual Meeting Abstracts) 2006 108: Abstract 2763© 2006 American Society of HematologyThis Article Services Email this article to a friend Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sacchi, S. Articles by Baldini, L. Search for Related Content PubMed Articles by Sacchi, S. Articles by Baldini, L. Social Bookmarking What's this? Poster Board #-Session: 941-II Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. Stefano Sacchi, MD1, Samantha Pozzi, MD1,*, Raffaella Marcheselli, BS1,*, Stefano Luminari, MD1,*, Massimo Federico, MD1, Alessandra Tucci, MD2,*, Francesco Merli, MD3,*, Loretta Orsucci, MD4,*, Giulia Cervetti, MD5,*, Ubaldo Occhini, MD6,*, Marina Liberati, MD7,*, Vincenzo Callea, MD8,*, Maura Brugiatelli, MD9 and Luca Baldini, MD10,* 1 Dipartimento di Oncologia ed Ematologia, Universita di Modena, Modena, Italy; 2 Dipartimento di Medicina Interna, Ospedale, Brescia, Italy; 3 Dipartimento di Ematologia, Ospedale, Reggio Emilia, Italy; 4 Dipartimento di Ematologia, Ospedale, Torino, Italy; 5 Dipartimento di Ematologia, Universita di Pisa, Pisa, Italy; 6 Servizio di Ematologia, Ospedale, Arezzo, Italy; 7 Ist. Scienze Oncologiche, Universita di Perugia, Perugia, Italy; 8 Dipartimento di Ematologia, Ospedale, Reggio Calabria, Italy; 9 Divisione di Ematologia, Ospedale, Messina, Italy and 10 Dipartimento di Scienze Mediche, Universita di Milano, Milano, Italy . AbstractFifty-four Pts entered this trial between January 2000 and December 2002. Eligible Pts had histologic documentation of CD 20+ relapsed FL, according to the revised European/American Lymphoma classification, that required treatment, measurable lesion, and an ECOG performance status of 0 or 1. Pts were further required to be aged 18–70 years, and to have undergone < 3 previous lines of chemotherapy. Pts received FC + R chemoimmunotherapy consisting of F 25 mg/m2 and C 300 mg/m2/day for 3 consecutive days every 3 weeks for 4 cycles. R 375 mg/m2 I.V. infusion was administered starting 2 weeks following the first FC course and then on day 1 of each cycle thereafter. Clinical response were defined according to the International Working Group recommendations. BCL 2 analysis was performed by PCR assay. DR, TTP and OS were analyzed by Kaplan-Meier method. Cox analysis was used to analyse the association of baseline prognostic factors with response to treatment, DR,TTP and OS. The overall response rate for all 54 Pts by ITT analysis was 90%; forty Pts (74%), obtained complete responses. Progression occurred in 3 Pts ( 6% ) and 2 Pts dropped out of the trial: 1 for toxicity and 1 refused to start with therapy. A univariate analysis of baseline prognostic factors demonstrated that none of these factors predicted for response to treatment. There were 29 Pts out of 45 tested, positive for BCL 2 before therapy. Among these, 22 Pts were evaluated after treatment and 19 ( 86%) converted to BCL negativity. At last follow up (FU), 40 Pts were alive, 31 with ongoing response and 9 with progressive disease. The median DR, TTP and OS have not been reached after a median FU time of 45 months ( range, 1 to 74 months ). The median DR in the 49 Pts who have reached CR or PR was 35 months ( range, 6 to 70 months). None of the baseline prognostic characteristics was significantly related to DR. The median TTP in all 54 Pts, was 36 months ( range, 1 to 74 months ).BCL2 positivity and < 2 previous treatments were related with better TTP (p<0.05 ) OS rate at 4 years was 75%. Toxicity was evaluable in 52 Pts. The most common severe side effects were hematologic, and included 21 cases of neutropenia, 3 cases of thrombocytopenia and 2 cases of anemia. Infectious complications manifested in 3 Pts and 1 died for pneumonitis. Treatment delays of 1–3 weeks was necessary in 12 patients. The results of our trial have demonstrated that FC+R chemoimmunotherapy is active and relatively well tolerated. The OR rate of 90%, associated with an excellent molecular remission rate, and the mean DR of 35 months compares favourably with the results obtained in other trials in similar subset of patients and supports the use of an FC+R arm in future controlled trials.
108
2763
2763
Sacchi, Stefano; Pozzi, Samantha; Marcheselli, Raffaella; Luminari, Stefano; Federico, Massimo; Alessandra, Tucci; Francesco, Merli; Loretta, Orsucci; Giulia, Cervetti; Ubaldo, Occhini; Marina, Liberati; Vincenzo, Callea; Maura, Brugiatelli; Luca, Baldini
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL / Sacchi, Stefano; Pozzi, Samantha; Marcheselli, Raffaella; Luminari, Stefano; Federico, Massimo; Alessandra, Tucci; Francesco, Merli; Loretta, Orsucci; Giulia, Cervetti; Ubaldo, Occhini; Marina, Liberati; Vincenzo, Callea; Maura, Brugiatelli; Luca, Baldini. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 108:(2006), pp. 2763-2763. ((Intervento presentato al convegno 48th ASH 2006 tenutosi a nd nel dic 2006.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/619180
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact